
William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

Your AI-Trained Oncology Knowledge Connection!


William K. Oh, MD, is the director of Precision Medicine at the Yale Cancer Center and Smilow Cancer Hospital, and service line medical director at the Smilow Cancer Hospital, Greenwich Hospital.

William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

William Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the management of patients with hormone-sensitive prostate cancer.

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Published: November 15th 2017 | Updated:

Published: February 17th 2017 | Updated: